231 related articles for article (PubMed ID: 35554920)
1. Biorisk Management for SARS-CoV-2 Research in a Biosafety Level-3 Core Facility.
Joseph T; Phyu S; Se-Thoe SY; Chu JJH
Methods Mol Biol; 2022; 2452():441-464. PubMed ID: 35554920
[TBL] [Abstract][Full Text] [Related]
2. Management System Approach for Addressing Biosafety and Biosecurity of Emerging Pathogens in a Biosafety Level-3 Core Facility.
Joseph T
Appl Biosaf; 2021 Dec; 26(4):210-220. PubMed ID: 36034099
[No Abstract] [Full Text] [Related]
3. Strengthening Biorisk Management in Research Laboratories with Security-Sensitive Biological Agents Like SARS-CoV-2.
Phyu S; Joseph T; Goulart M
Methods Mol Biol; 2022; 2452():395-439. PubMed ID: 35554919
[TBL] [Abstract][Full Text] [Related]
4. Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis.
Mourya DT; Sapkal G; Yadav PD; M Belani SK; Shete A; Gupta N
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):172-176. PubMed ID: 32242878
[TBL] [Abstract][Full Text] [Related]
5. Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.
Kaufer AM; Theis T; Lau KA; Gray JL; Rawlinson WD
Pathology; 2020 Dec; 52(7):790-795. PubMed ID: 33070960
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the establishment of a biosafety testing laboratory for COVID-19 in Bangladesh.
Islam SRU; Akther T; Sultana S; Deb P; Ghosh AK; Nasif MAO; Bhuiyan AH; Jahan M; Nessa A; Munshi SU; Tabassum S
J Infect Dev Ctries; 2021 Dec; 15(12):1833-1837. PubMed ID: 35044940
[TBL] [Abstract][Full Text] [Related]
7. Assessment of biorisk management systems in high containment laboratories, 18 countries in Europe, 2016 and 2017.
Appelt S; Jacob D; Rohleder AM; Bråve A; Szekely Björndal Å; Di Caro A; Grunow R;
Euro Surveill; 2020 Sep; 25(36):. PubMed ID: 32914748
[TBL] [Abstract][Full Text] [Related]
8. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.
Lippi G; Adeli K; Ferrari M; Horvath AR; Koch D; Sethi S; Wang CB
Clin Chem Lab Med; 2020 Jun; 58(7):1053-1062. PubMed ID: 32396137
[TBL] [Abstract][Full Text] [Related]
9. Biosafety and biosecurity measures: management of biosafety level 3 facilities.
Zaki AN
Int J Antimicrob Agents; 2010 Nov; 36 Suppl 1():S70-4. PubMed ID: 20801002
[TBL] [Abstract][Full Text] [Related]
10. A Cross-Sectional Survey to Assess Biorisk Management System in Research and Diagnostic Laboratories in Khyber Pakhtunkhwa, Pakistan.
Muhammad J; Sarwar S; Khan T; Qasmi SA; Ikram A; Ahmad G; Zahid M; Durrani RH; Ahmed F
Front Public Health; 2021; 9():766162. PubMed ID: 34976925
[TBL] [Abstract][Full Text] [Related]
11. The Biosafety Research Road Map: The Search for Evidence to Support Practices in the Laboratory-SARS-CoV-2.
Blacksell SD; Dhawan S; Kusumoto M; Le KK; Summermatter K; O'Keefe J; Kozlovac J; Almuhairi SS; Sendow I; Scheel CM; Ahumibe A; Masuku ZM; Kojima K; Harper DR; Hamilton K
Appl Biosaf; 2023 Jun; 28(2):87-95. PubMed ID: 37342515
[TBL] [Abstract][Full Text] [Related]
12. Laboratory Biosafety Considerations of SARS-CoV-2 at Biosafety Level 2.
Wang K; Zhu X; Xu J
Health Secur; 2020; 18(3):232-236. PubMed ID: 32522074
[TBL] [Abstract][Full Text] [Related]
13. [Biorisk Management for Clinical Diagnostic Laboratories].
Shigematsu M
Rinsho Byori; 2016 Nov; 64(11):1279-1289. PubMed ID: 30695310
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of international virtual training on biorisk management in the context of COVID-19.
Qasmi SA; Standley C; Mohsin S; Sarwar S; Malik L; Aziz F
Front Public Health; 2022; 10():888097. PubMed ID: 36339241
[TBL] [Abstract][Full Text] [Related]
15. Certification & validation of biosafety level-2 & biosafety level-3 laboratories in Indian settings & common issues.
Mourya DT; Yadav PD; Khare A; Khan AH
Indian J Med Res; 2017 Oct; 146(4):459-467. PubMed ID: 29434059
[TBL] [Abstract][Full Text] [Related]
16. Biosafety Requirements for Autopsies of Patients with COVID-19: Example of a BSL-3 Autopsy Facility Designed for Highly Pathogenic Agents.
Loibner M; Langner C; Regitnig P; Gorkiewicz G; Zatloukal K
Pathobiology; 2021; 88(1):37-45. PubMed ID: 33296902
[TBL] [Abstract][Full Text] [Related]
17. Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.
Reifel KM; Swan BK; Jellison ER; Ambrozak D; Baijer J; Nguyen R; Monard S; Lyon G; Fontes B; Perfetto SP
Cytometry A; 2020 Jul; 97(7):674-680. PubMed ID: 32488957
[TBL] [Abstract][Full Text] [Related]
18. Challenges in Implementing a Biorisk Management Program at Universitas Indonesia: A Checklist Tool for Biorisk Management.
Naroeni A; Bachtiar EW; Ibrahim F; Bela B; Kusminanti Y; Pujiriani I; Lestari F
Health Secur; 2016; 14(6):375-381. PubMed ID: 27830940
[TBL] [Abstract][Full Text] [Related]
19. Assessment of inactivation procedures for SARS-CoV-2.
Auerswald H; Yann S; Dul S; In S; Dussart P; Martin NJ; Karlsson EA; Garcia-Rivera JA
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416462
[TBL] [Abstract][Full Text] [Related]
20. A Multilingual Tool for Standardized Laboratory Biosafety and Biosecurity Assessment and Monitoring.
Orelle A; Nikiema A; Zakaryan A; Albetkova AA; Keita MS; Rayfield MA; Peruski LF; Pierson A
Health Secur; 2022; 20(6):488-496. PubMed ID: 36383124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
